Omkar Speciality Chemicals Limited · NSE:OMKARCHEM
Omkar Speciality Chemicals — Q3 FY16 Earnings Presentation
30 slides from Omkar Speciality Chemicals's earnings presentation, February 2016
Slide 1: Omkar Speciality Chemicals Limited Result Presentation Q3 FY16
Omkar Speciality Chemicals Limited Result Presentation Q3 FY16
Slide 2: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Omkar Speciality Chemicals Limited (the “Company”) solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, an
Slide 3: Q3 & 9M FY16 Business Update
Always the leaders Q3 & 9M FY16 — Business Update
Slide 4: Business Update
Business Update Consolidated (INR crore) Q3 FY16 YoY 9M FY16 YoY Revenue 108 52.7% 300 56.9% EBITDA 18 8.8% 53 39.0% EBITDA Margin (%) 16.2% - 17.7% - PAT 9 25.5% 27 41.0% Robust revenue growth in Q3FY16 and 9MFY16 – on account of growth across all business segments EBITDA margins of 16.2% durin
Slide 5: Consolidated Profitability Highlights
Consolidated Profitability Highlights INR Crore Q3 FY16 Q3 FY15 YoY Q2 FY16 QoQ 9M FY16 9M FY15 YoY Revenue from Operations 108 71 52.7% 101 7.0% 300 191 56.9% Raw Material & Fuel costs 80 45 72 215 123 Employee Cost 4 3 4 13 11 Other costs 6 6 6 20 20 Total Expenditure 91 55 83 247 153 EBIDTA 18 16
Slide 6: Segment & Geographical Revenue Split – Q3FY16
Segment & Geographical Revenue Split – Q3FY16 Segment break-up Geographical break-up Intermediates Exports Selenium 37% 4% Derivatives 2% Iodine Derivatives 23% Resolving API Agents 36% 2% Domestic 96% 6
Slide 7: Segment & Geographical Revenue Split – 9MFY16
Segment & Geographical Revenue Split – 9MFY16 Segment break-up Geographical break-up Intermediates 41% Exports 16% Selenium Derivatives 3% Iodine Derivatives 22% API 32% Domestic Resolving 84% Agents 2% 7
Slide 8: Key Performance Indicators
Key Performance Indicators Return on Equity Return on Capital Employed 15.5% 15.0% 17.9% 17.6% 13.8% 17.1% 13.6% 15.5% 10.2% 9.7% FY12 FY13 FY14 FY15 9M FY16 FY12 FY13 FY14 FY15 9M FY16 Note: 9M FY16 returns on TTM basis; ROE = PAT/ Networth; ROCE = EBIT/ Capital Employed 8
Slide 9: Key Performance Indicators
Key Performance Indicators Debt on books (Rs Crore) Net working capital (Days) 203 202 205 191 177 145 143 144 95 94 FY12 FY13 FY14 FY15 9M FY16 FY12 FY13 FY14 FY15 9M FY16 9
Slide 10: Corporate Overview
HAiiWwilZfelfe OMKAR Always the leaders Corporate Overview
Slide 11: Corporate Overview
Corporate Overview Amongst leading players in organic and inorganic intermediates and APIs (Active Pharmaceutical Ingredients) In house manufacturing units & DSIR approved R&D Centre • 8 units & 1 centralized warehouse in Thane, Ratnagiri and Raigad Districts, Maharashtra Manufactures more than 200
Slide 12: Corporate Structure
Corporate Structure 100% 100% 100% 100% Lasa Laboratory Pvt. Urdhwa Chemicals Ltd. Rishichem Research Desh Chemicals Pvt. Company Pvt. Ltd. Limited Ltd. 12
Slide 13: Evolved to Manufacture more than 200 Products
Evolved to Manufacture more than 200 Products… Expanded capacities in Unit I, Production of iodine V, VI and Lasa derivatives & Selenium Organic Intermediates Leading player offering more than 200 products across organic, Incorporated Omkar inorganic intermediates and APIs Speciality Chemica
Slide 14: Professional Management
Professional Management Core Promoter with 40 years of experience in Product Development, Marketing and Administration Bachelor of Technology in Chemical Engineering from IIT, Mumbai, Post graduate in Pravin Herlekar, management studies from Mumbai University CMD Successful in expanding custom
Slide 15: Business Overview
7) 1474091 OMKAR Always the leaders Business Overview
Slide 16: Business Segments
Business Segments Organic & Inorganic Intermediates • Used in Digital applications, Reagent in pharma industry, Pigments and Building blocks in organic chemistry Iodine Compounds • Used as Reagent in pharma industry, Intermediate for API, Screen printing and Animal feed formulations Selenium Compoun
Slide 17: In-house Volumetric Capacity totaling 5,250 MTPA
In-house Volumetric Capacity totaling to 5,250 MTPA… Unit I, Badlapur Unit II, Badlapur Unit III, Badlapur Inorganic Intermediates Organic Intermediates Inorganic Intermediates Unit IV, Badlapur Unit V, Chiplun Unit VI, Chiplun Centralized Warehouse Organic Intermediates Organic Intermediates 17
Slide 18: In-house Volumetric Capacity totaling 5,250 MTPA
In-house Volumetric Capacity totaling to 5,250 MTPA… Lasa, Mahad Urdhwa, Chiplun Rishi Chem, Badlapur APIs (Veterinary) Organic Intermediates Pilot plant -product commercialization …In line with next two years of growth 18
Slide 19: Strong R&D team
Strong R&D team • DSIR recognized R&D unit • Creates catalysts for high yield production of products • Responsible for process patents • Acquired Rishichem Research Limited – unit equipped with pilot plant facilities 19
Slide 20: Wide Customer Base
Wide Customer Base OMKAR Always the leaders Cipla @ LUPIN Ball 4 wy =Sevonik @osm__ WOQHARDY SANOFI Honeywell (f)Mytlan 6 (Ipca) Glenmark (Ipea) ) MERCK €ea MaRex sion ee I 2 “I "ler, pea Uaboratore Cte a") aman ox U) Novartis Y dx.Reooys Iesamilebel 4 Conovel = Netchem Inc. MENADIONA Pe ire @ sam A
Slide 21: Global Footprints across 40 Countries
Global Footprints across 40 Countries 21
Slide 22: Key Business Strengths & Growth Strategy
Key Business Strengths & Growth Strategy
Slide 23: Key Business Strengths
Key Business Strengths Develops catalysts – used in Amongst few players in India, manufacturing process of APIs to wide product suite and intermediates – that leads More than 200 products to higher yields and better developed in-house Work profitability Environment 18 Process patents and 15
Slide 24: Backward Integration Initiatives
Backward Integration Initiatives… Name of Intermediate Name of Final Finished Product 4-Bromobenzene -1,2 2-Nitroaniline Albendazole Ricobendazole Diamine 5-Chloro-2-Nitroaniline Fenbendazole Oxfendazole Atipa-Dichloride Iohexol Iopamidol 2-Hydroxy-3,5-Diiodo Benzoic Acid Closantel Rafoxanide 2-Amin
Slide 25: Focus On Niche Specialty Chemicals For Upcoming Market
Focus On Niche Specialty Chemicals For Upcoming Market Product Segment API Application 5-Iodo-2-Methyl Benzoic Acid (a) Iodine Compound Canagliflozin Anti-Diabetic 2-Chloro-5-Iodobenzoic Acid Iodine Compound Empagliflozin Anti-Diabetic 4-bromo-1, 2-benzenediamine Intermediate Ledipasvir Hepatitis C
Slide 26: Growth Strategy
Growth Strategy Product Manufacturing Customer/ Market • Focus on existing higher • Fungible manufacturing • Increase exports - both in margin products like capabilities value and markets, by Intermediates and APIs leveraging expertise and • Catalyst driven process cost competitiveness • New product
Slide 27: Financial Highlights
HAiiWwilZfelfe OMKAR Always the leaders Financial Highlights
Slide 28: Annual Consolidated Profitability Highlights
Annual Consolidated Profitability Highlights INR-Crore TTM FY15 FY14 Revenue from Operations 374.0 265.1 240.3 Other Income 0.9 0.9 3.3 Total Income 374.9 266.0 243.5 Raw Material & Fuel Costs 259.8 167.7 161.1 Employee Cost 16.4 14.4 13.9 Other Cost 30.7 30.9 22.3 Total Expenditure 306.9 213.0 197.
Slide 29: Segment & Geographical Revenue Split – FY15
Segment & Geographical Revenue Split –FY15 Segment break-up Geographical break-up Selenium Derivatives 6% Intermediates Exports 20% 25% Iodine Derivatives 48% API 22% Domestic 75% Resolving Agents 4% 29
Slide 30: For further information, please contact
For further information, please contact: Company : Investor Relations Advisors : Omkar Speciality Chemicals Ltd Stellar IR Advisors Pvt. Ltd. CIN: L24110MH2005PLC151589 CIN: U74900MH2014PTC259212 Mr. Pravin Agrawal Ms. Savli Mangle agrawal@omkarchemicals.com msavli@stellar-ir.com Mr. Vikash Verma vi
Omkar Speciality Chemicals — Q3 FY16 Earnings Presentation on 6ix